CBD

Cannabidiol (CBD) is a phytocannabinoid — one of over one hundred cannabinoids identified in Cannabis sativa — that lacks the intoxicating effects of Δ⁹‑tetrahydrocannabinol (THC) because it binds only weakly to the brain’s CB₁ receptors. First isolated in 1940 by Roger Adams at the University of Illinois, CBD’s structure was elucidated in 1963 by Raphael Mechoulam’s team at the Hebrew University of Jerusalem, establishing the chemical foundation for modern research. Unlike THC, CBD does not produce a “high,” a property that has propelled it into clinical trials, nutraceuticals, and a rapidly expanding global market. The U.S. Food and Drug Administration (FDA) granted the first prescription‑only CBD product, Epidiolex, in June 2018 for two rare forms of epilepsy, marking the compound’s transition from botanical curiosity to regulated medicine. Since that approval, CBD has become a focal point for scientists, regulators, and entrepreneurs seeking to harness its purported therapeutic benefits without psychoactive risk. ## Historical Background Industrial hemp, a low‑THC variety of C. sativa, was cultivated in China as early as 2700 BCE for fiber, and archaeological residues suggest that cannabinoids were used medicinally in ancient India by 1000 CE. Modern scientific interest surged after the 1963 synthesis of CBD, which enabled the first pharmacological studies by the 1970s at the National Institute on Drug Abuse (NIDA). In 1976, the United Nations Commission on Narcotic Drugs classified cannabis as a Schedule I substance, but the World Health Organization (WHO) retained CBD in a separate “non‑controlled” category in its 2017 Expert Committee review, citing a lack of abuse potential. The 2018 U.S. Farm Bill subsequently removed hemp‑derived CBD (containing ≤0.3 % THC) from the Controlled Substances Act, creating a legal pathway for commercial production and research. ## Mechanism of Action CBD interacts with the endocannabinoid system (ECS) primarily as a negative allosteric modulator of CB₁ receptors, dampening the receptor’s response to THC and endogenous anandamide. It also inhibits the enzyme fatty‑acid amide hydrolase (FAAH), raising anandamide levels by up to 30 % in rodent models, which may underlie its anxiolytic effects. Beyond the ECS, CBD acts as an agonist at the 5‑HT₁A serotonin receptor, a target implicated in mood regulation, and as an antagonist of the GPR55 receptor, which influences calcium signaling in neuronal cells. These multimodal actions collectively contribute to CBD’s reported anti‑convulsant, anti‑inflammatory, and neuroprotective properties, although the relative contribution of each pathway remains under investigation. ## Therapeutic Applications Clinical evidence for CBD began with randomized, double‑blind trials in 2017 that demonstrated a 43 % reduction in monthly seizure frequency among children with Dravet syndrome receiving 20 mg kg⁻¹ day⁻¹ of CBD. The FDA’s 2018 approval of Epidiolex, derived from purified plant CBD, was based on two pivotal Phase III studies involving 214 participants, which confirmed statistically significant seizure reductions compared with placebo. Subsequent open‑label extensions reported sustained efficacy over a median of 48 weeks, with adverse events limited to somnolence and elevated liver enzymes in less than 10 % of patients. Outside epilepsy, a 2020 meta‑analysis of 31 trials involving 2,500 participants found that CBD reduced anxiety scores by an average of 31 % on the Hamilton Anxiety Rating Scale, while a 2021 systematic review highlighted modest analgesic effects in chronic pain cohorts. The WHO’s 2017 monograph concluded that CBD exhibits a favorable safety profile, noting no evidence of dependence or withdrawal in human studies. ## Regulatory Landscape In the United States, the FDA classifies over‑the‑counter CBD products as “dietary supplements,” a designation that conflicts with its status as a new drug under the Federal Food, Drug, and Cosmetic Act, prompting the agency to issue a 2022 warning letter to 15 manufacturers for unapproved health claims. The European Union granted “novel food” authorization for CBD extracts in 2021, stipulating a maximum of 0.2 % THC and requiring a 30‑day safety assessment for each product batch. Canada legalized cannabis, including CBD, for medical and recreational use in October 2018 under the Cannabis Act, imposing a federal ceiling of 10 % THC for CBD‑rich oils. Meanwhile, the United Nations re‑scheduled cannabis in December 2020, moving it from Schedule IV to Schedule I, but retained a distinct entry for CBD, reflecting its non‑psychoactive status. These divergent frameworks have created a patchwork of permissible